salt-inducible kinase 2 selective inhibitor

Salt-inducible kinase 2 (SIK2) selective inhibitors represent an emerging class of oral small molecule therapeutics designed to treat inflammatory conditions, particularly Ulcerative Colitis and other forms of Inflammatory Bowel Disease (IBD). Developed by Nimbus Therapeutics, these compounds are engineered for high potency and significant selectivity (>300-fold) over other SIK isoforms (SIK1 and SIK3). SIK2 plays a critical role in myeloid cell signaling; its inhibition suppresses the production of key proinflammatory cytokines such as TNFα, IL-23, and IL-1β. Uniquely, selective SIK2 inhibition also enhances the production of the anti-inflammatory cytokine IL-10 and promotes mucosal healing by upregulating genes like mucin-2 and occludin. This dual mechanism of action—combining potent anti-inflammatory effects with tissue-reparative benefits—positions SIK2 inhibitors as a potentially differentiated therapeutic approach compared to existing treatments like JAK inhibitors.

Other names

SIK2 selective inhibitorSIK-2 selective inhibitorSIK 2 selective inhibitorsalt-inducible kinase 2 inhibitor